ELI LILLY & Co (LLY)
Pharmaceutical Preparations
Latest Price
$1148.84
TTM P/E
40.81
Normalized P/E
92.93
Div Yield
0.54%
Book Value
34.88
P/B Ratio
32.94
Valuation metrics
adjust assumptions →EPS: $22.95
Book value / share: $29.51
Formula: √(22.5 × EPS × BVPS)
Graham Number
$123.44
89% downside
Norm. op. income: $7.1B (median of 7yr)
Tax rate: 14%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$28.99
97% downside
Base FCF: $5.2B (median of recent 5yr)
Growth: 21%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$278.09
76% downside
EPS: $22.95
Target P/E: 93×
Formula: EPS × P/E
P/E Fair Value
$2,134.35
+86% upside
Institutional Ownership
85.2% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | 91.90M | $84.52B | 10.27% | -293.5K | 2026-03-31 |
| BlackRock, Inc. | 66.49M | $61.16B | 7.43% | -299.0K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 53.36M | $49.08B | 5.97% | -- | 2026-03-31 |
| PNC Financial Services Group, Inc. | 51.33M | $47.21B | 5.74% | -4.3K | 2026-03-31 |
| STATE STREET CORP | 35.61M | $32.75B | 3.98% | +248.1K | 2026-03-31 |
| FMR LLC | 26.34M | $24.23B | 2.94% | +619.4K | 2026-03-31 |
| Capital Research Global Investors | 24.63M | $22.65B | 2.75% | +65.8K | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 20.98M | $19.29B | 2.35% | -- | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 20.19M | $18.51B | 2.26% | +381.8K | 2026-03-31 |
| Capital World Investors | 15.62M | $14.37B | 1.75% | +590.1K | 2026-03-31 |